Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samah Alimam

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
American Journal of Hematology|May 14, 2026
Accuracy of Diagnosis in Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis (MPN-SVT)Bharath Ram Sreedhar, Hosuk Ryou, Aoife O'Riordan, et al.
British Journal of Haematology|May 16, 2019
Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experienceJoana Desterro, Donal P McLornan, Natalia Curto Garcia, et al.
British Journal of Haematology|November 7, 2020
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasmsSamah Alimam, Jessica Ann Timms, Claire N Harrison, et al.
Blood|October 4, 2019
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinibJennifer M O'Sullivan, Angela Hamblin, Christina Yap, et al.
Current Research in Translational Medicine|January 23, 2024
Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'Dipal Mehta, Samah Alimam, Donal P McLornan, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Blood|January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AMLRichard Dillon, Robert Hills, Sylvie Freeman, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
American Journal of Hematology|May 14, 2026
Accuracy of Diagnosis in Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis (MPN-SVT)Bharath Ram Sreedhar, Hosuk Ryou, Aoife O'Riordan, et al.
British Journal of Haematology|May 16, 2019
Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experienceJoana Desterro, Donal P McLornan, Natalia Curto Garcia, et al.
British Journal of Haematology|November 7, 2020
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasmsSamah Alimam, Jessica Ann Timms, Claire N Harrison, et al.
Blood|October 4, 2019
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinibJennifer M O'Sullivan, Angela Hamblin, Christina Yap, et al.
Current Research in Translational Medicine|January 23, 2024
Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'Dipal Mehta, Samah Alimam, Donal P McLornan, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Blood|January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AMLRichard Dillon, Robert Hills, Sylvie Freeman, et al.
Pageof 2